Type 2 diabetes mellitus and biomarkers of neurodegeneration

Neurology

Volumn 85, Issue 13, 2015, Pages 1123-1130

  Moran, Chris ^a,b,c   Beare, Richard ^d   Phan, Thanh G ^a,b   Bruce, David G ^e   Callisaya, Michele L ^f   Srikanth, Velandai ^a,b,f  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c Caulfield General Medical Centre   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B; TAU PROTEIN;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN REGION; BRAIN SIZE; COGNITION; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROIMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL GYRUS; PRECENTRAL SULCUS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; BRAIN CORTEX; CEREBROSPINAL FLUID; DEGENERATIVE DISEASE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; CEREBRAL CORTEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; TAU PROTEINS;

EID: 84948978519     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001982     Document Type: Article

References (40)

1. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002;51:1256-1262.
2. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006;5:64-74.
3. den Heijer T, Vermeer SE, van Dijk EJ, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003;46:1604-1610.
4. Knopman DS, Penman AD, Catellier DJ, et al. Vascular risk factors and longitudinal changes on brain MRI: the ARIC Study. Neurology 2011;76:1879-1885.
5. Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care 2013;36:4036-4042.
6. Tomita N, Furukawa K, Okamura N, et al. Brain accumulation of amyloid beta protein visualized by positron emission tomography and BF-227 in Alzheimer's disease patients with or without diabetes mellitus. Geriatr Geron-tol Int 2013;13:215-221.
7. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-344.
8. Reitz C. Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis 2012; 2012:369808.
9. Apostolova LG, Hwang KS, Andrawis JP, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 2010;31:1284-1303.
10. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
11. McKhann G, Drachman D, Folstein M, Katzman R Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
12. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-637.
13. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(suppl 1):S11-S61.
14. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685-691.
15. Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009;6:347-361.
16. ADNI. MRI pre-processing. Available at: http://adni.loni. usc.edu/methods/mri-analysis/mri-pre-processing/. Accessed December 8, 2013.
17. Destrieux C, Fischl B, Dale A, Halgren E. Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. Neuroimage 2010;53:1-15.
18. Schwarz C, Fletcher AE, DeCarli C, Carmichael OT. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR Inf Process Med Imaging 2009;21:239-251.
19. DeCarli C, Carmichael OT, He J. MRI infarct assessment in ADNI. 2013. Available at: http://adni.bitbucket.org/docs/MRI-INFARCTS/UCD%20ADNI%20MRI%20Infarct% 20Assessment%20Method.pdf. Accessed August 17, 2013.
20. ADNI. PET pre-processing. Available at: http://adni.loni.usc. edu/methods/pet-analysis/pre-processing/. Accessed August 16, 2013.
21. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010;6:221-229.
22. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol 2009; 65:403-413.
23. Brundel M, van den Heuvel M, de Bresser J, Kappelle LJ, Biessels GJ. Cerebral cortical thickness in patients with type 2 diabetes. J Neurol Sci 2010;299:126-130.
24. Jung HJ, Kim YJ, Eggert S, Chung KC, Choi KS, Park SA. Age-dependent increases in tau phosphorylation in the brains of type 2 diabetic rats correlate with a reduced expression of p62. Exp Neurol 2013;248:441-450.
25. Arvanitakis Z, Schneider JA, Wilson RS, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006;67:1960-1965.
26. Heitner J, Dickson D. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects: a retrospective postmortem immunocytochemical and histofluorescent study. Neurology 1997;49:1306-1311.
27. Thambisetty M, Metter EJ, Yang A, et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol 2013;70:1167-1172.
28. Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010;75:1195-1202.
29. Beeri MS, Silverman JM, Davis KL, et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropa-thology. J Gerontol A Biol Sci Med Sci 2005;60:471-475.
30. Nelson PT, Smith CD, Abner EA, et al. Human cerebral neuropathology of type 2 diabetes mellitus. Biochim Bio-phys Acta 2009;1792:454-469.
31. Munch G, Westcott B, Menini T, Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids 2012;42:1221-1236.
32. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem 2009;111:242-249.
33. Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014;63:2253-2261.
34. Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neuro-filaments in the brain: implication for Alzheimer's disease. Am J Pathol 2009;175:2089-2098.
35. Yang Y, Ma D, Wang Y, et al. Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. J Alzheimers Dis 2013;33:329-338.
36. Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol 2014;2:246-255.
37. National Center for Chronic Disease Prevention and Health Promotion. National diabetes statistics report, 2014. Atlanta: Centers for Disease Control and Prevention; 2014.
38. Roberts RO, Knopman DS, Cha RH, et al. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med 2014;55:759-764.
39. Alafuzoff I, Aho L, Helisalmi S, Mannermaa A, Soininen H. Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurobiol 2009;35: 60-68.
40. Jeerakathil T, Wolf PA, Beiser A, et al. Stroke risk profile predicts white matter hyperintensity volume: the Framing-ham Study. Stroke 2004;35:1857-1861.